Drug Type Small molecule drug |
Synonyms 3-(2,4-dimethoxybenzylidene)anabaseine, 3-2,4 dimethoxy-benzilidene anabaseine, Dimethoxybenzylidene anabaseine + [4] |
Target |
Mechanism α7 receptor agonists(Neuronal acetylcholine receptor protein alpha-7 subunit agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H22Cl2N2O2 |
InChIKeyBXKYFUGAAFLYJL-BXGYHSFXSA-N |
CAS Registry156223-05-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Attention Deficit Disorder With Hyperactivity | Phase 2 | US | 01 Feb 2007 | |
Alzheimer Disease | Phase 2 | US | 01 Nov 2006 | |
Schizophrenia | Phase 2 | US | 01 Jan 2005 | |
Cognition Disorders | Phase 2 | US | - | |
Cognition Disorders | Phase 2 | - | - | |
Autistic Disorder | Phase 1 | - | - | |
Autistic Disorder | Phase 1 | - | - |
Phase 1 | 61 | (DMXB-A) | iwuuqdxseq(dhyuwsapor) = lhtskbwidh uxmjgfznsp (kkygagrpup, ykvknkvmad - opihfvlvof) View more | - | 12 Jun 2023 | ||
Placebo (Placebo) | iwuuqdxseq(dhyuwsapor) = jovqnpvthf uxmjgfznsp (kkygagrpup, hflobhtjdt - pfvaspagfv) View more | ||||||
Phase 2 | 29 | Placebo | kkhnxvxkph(izqbwuvyta) = shvmupenyj ncmryppeuf (xtgxihzxbz, okzjkoplbk - khogqdxzlg) View more | - | 29 Jan 2020 | ||
Phase 2 | 97 | (DMXB-A-SR) | iiqenopjfo(hwbhcaimbr) = iwztcyvbib ocyvxzuzvr (nygfdxwmgs, inpcrryprk - jpocgzbmvm) View more | - | 07 May 2019 | ||
Placebo (Arm #2: Placebo Comparator) | iiqenopjfo(hwbhcaimbr) = tiuhlceaig ocyvxzuzvr (nygfdxwmgs, pmdkwoyhzd - pvzudqhykn) View more |